Tirbanibulin
Tirbanibulin, sold under the brand name Klisyri, is a medication used for the treatment of actinic keratosis on the face or scalp. It functions by inhibiting both tubulin polymerization and Src kinase signaling. It is potentially effective in impeding the development of squamous cell carcinoma in situ.
The most common side effects include local skin reactions, application site pruritus, and application site pain.
Tirbanibulin was approved for medical use in the United States in December 2020, and in the European Union in July 2021. The US Food and Drug Administration considers it to be a first-in-class medication.
Medical uses
Tirbanibulin is indicated for the topical treatment of actinic keratosis of the face or scalp.Mechanism of Action
Tirbanibulin, chemically known as N-benzyl-2- acetamide, is a microtubule and non–ATP-competitive inhibitor. The drug in various ways mimics the mechanisms of chemotherapy by suspending the protooncogenic Src tyrosine kinase signaling pathway. Notably, it promotes G2/M arrest during cell cycle, upregulates p53, and triggers apoptosis via caspase-3 stimulation and poly polymerase cleavage.Side effects
In several studies tirbanibulin has been observed to induce skin reactions at the site of application, ranging from mild to severe erythema, flaking, ulceration, and pain.Extensive research has not been conducted on the risks of tirbanibulin usage by specific human populations. Significant differences have not been observed in the safety or effectiveness of tirbanibulin between geriatric or pediatric populations.